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Objectives: 
 
1.  Review the background, epidemiology, and diagnostic criteria for the 
antiphospholipid syndrome 
2.  List clinical manifestations associated with antiphospholipid syndrome 
3.  Describe the pathophysiology of thrombosis in the antiphospholipid syndrome 
4.  Evaluate the evidence for the different intensities of oral anticoagulation in the 
antiphospholipid syndrome 
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I.  Introduction 
 
1.  Background
1-3 
i.  Antiphospholipid syndrome (APS) is an autoimmune disease 
characterized by the presence of antiphospholipid antibodies (aPL), 
vascular thrombosis, and/or recurrent fetal loss 
1.  Primary APS  
a.  Presence of antibodies in patients with vascular 
thrombosis or pregnancy morbidity  
2.  Secondary APS 
a.  APS occurs with other conditions such as systemic lupus 
erythematosus (SLE) 
3.  Catastrophic APS 
a.  Accelerated form of APS  
b.  Specific classification criteria available which includes 
multi- system organ failure 
c.  Associated with a 50% mortality rate 
 
2.  History
1-2,4-5 
i.  Antiphospholipid antibody was first detected in patients with syphilis in 
1906 
ii.  Syphilis screening led to the finding that many patients with SLE had a 
positive Venereal Disease Research Laboratory (VDRL) test with no 
clinical manifestations of syphilis 
iii.  An anticoagulant associated with SLE was later discovered in 1952 
iv.  In 1963, a relationship between circulating anticoagulants in SLE and 
thrombosis was established 
v.  The circulating anticoagulants were termed “lupus anticoagulants” (LA) 
and associated with thrombosis and spontaneous abortions  
vi.  An immunoassay that was more sensitive than VDRL to detect 
anticardiolipin antibodies (aCL) was later created in 1983 
 
 
II.  Epidemiology
1,5-6 
i.  APS is the most common cause of hypercoagulability in the general 
population 
ii.  Antiphospholipid antibodies (LA and aCL) are found in 1 to 5% of 
young, healthy adults 
iii.  aCL and LA are present together in approximately 38% of patients with 
aPL 
iv.  More common in young to middle-aged adults  
v.  More common in  females, especially secondary APS 
vi.  No defined racial predominance  
vii.  Prevalence of antiphospholipid antibodies is higher in SLE 
1.  Approximately 12 to 30% for aCL 
2.  Approximately 15 to 34% for LA 
viii.  Associated with a higher incidence of thrombosis 
 
 
 
Abbreviations 
APS=Antiphospholipid 
syndrome   
aPL=Antiphospholipid 
antibodies 
SLE=Systemic Lupus 
Erythematosus 
VDRL= Venereal Disease 
Research Laboratory  
LA=Lupus Anticoagulant 
aCL=anticardiolipin 
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III.  Table 1: Clinical Manifestations 
1,5-7 
Peripheral venous 
system 
 
•  Venous thrombosis is the most common clinical manifestation 
•  29-55% of cases manifest as deep venous thrombosis 
o  Half of these cases also present with pulmonary embolism 
(PE) 
Central nervous 
system 
 
•  Approximately 50% of arterial thrombosis cases manifest as 
cerebral ischemia.
  
Cardiac 
 
•  Associated with increased risk of atherosclerosis and coronary 
artery disease 
•  Approximately 4% of patients with primary or secondary APS 
have mitral or aortic vegetations 
Dermatologic  
 
•  Livedo reticularis is a red or blue, reticular or mottled pattern on 
the trunk, arms, or legs 
•  Occurs in 11-22% of patients and is more prevalent in those 
patients with SLE and females 
Renal 
 
•  Involves lesions of renal small-artery and chronic renal ischemia 
Obstetric 
 
•  Manifests as pregnancy loss and eclampsia 
Hematologic 
 
•  Hemolytic anemia occurs in 14-23% of patients 
•  Thrombocytopenia
  occurs in 40-50% of patients
 and is more 
common in patients with both APS and SLE 
•  Also is associated with idiopathic thrombocytopenic purpura (ITP) 
 
IV.  Antiphospholipid antibodies (aPL) 
2,5-10 
1.  Anticardiolipin antibodies 
i.  Antibodies target a protein, cardiolipin and promote a prothrombotic 
endothelial surface 
ii.  IgG, IgM, and IgA are the three main isotypes 
1.  IgG isotype is most strongly associated with thrombosis 
iii.  Method of detection is anticardiolipin enzyme-linked immunosorbent 
assay (ELISA) 
iv.  Occurs more often than LA and is associated with venous and arterial 
thrombosis 
2.  Lupus Anticoagulants (LA) 
i.  Non-specific inhibitor of coagulation factors  
ii.  LA isotypes include IgG, IgM, IgA, or a combination 
iii.  Prolongs phospholipid-dependent tests of coagulation 
1.  Prothrombin time (PT) 
2.  Activated partial thromboplastin time (APTT) 
3.  Kaolin clotting time (KCT) 
4.  Dilute Russell’s viper venom time [dRVVT] 
iv.  Method of detection is coagulation assays 
v.  LA is a strong risk factor for thrombosis and is more commonly 
associated with thrombosis and pregnancy morbidity 
vi.  Associated with thrombosis in SLE patients 
 
 
 
APS=Antiphospholipid 
syndrome     
SLE=Systemic Lupus 
Erythematosus   
ITP= idiopathic 
thrombocytopenia 
purpura  
aPL=Antiphospholipid 
antibodies  
ELISA=Enzyme-linked 
immunosorbent assay 
aCL=Anticardiolipin 
antibodies 
LA= Lupus anticoagulant 
PT= Prothrombin Time 
APTT= Activated partial 
thromboplastin time 
KCT= Kaolin clotting 
time 
dRVVT= Diulte Russell’s 
viper venom time 
Abbreviations  Page 4 of 19 
 
3.  Anti-ß2-Glycoprotein I antibodies 
i.  ß2-Glycoprotein I is also known as apolipoprotein H and is a naturally 
occurring anticoagulant 
ii.  ß2-Glycoprotein I is the predominant target of aPL 
iii.  Antibodies bind and inhibit activation of the intrinsic coagulation 
pathway, platelet prothrombinase activity, and also induce platelet 
aggregation 
iv.  Anti-ß2-Glycoprotein I antibody isotypes include IgG and IgM  
v.  Method of detection is ELISA 
vi.  Presence of Anti- ß2-Glycoprotein I Antibodies is an independent risk 
factor for thrombosis 
 
 
V.  Pathophysiology  
Table 2: Several proposed mechanisms
1,4-7,10-11 
Activation of endothelial cells 
 
•  aPL bind to ß2-Glycoprotein I and prothrombin 
which activates endothelial cells
, 
•  Leads to upregulation of expression of adhesion 
molecules and secretion of cytokines, and 
metabolism of prostacyclines resulting in 
hypercoagulability 
Oxidant-mediated injury of the 
endothelium 
 
•  Antibodies may develop to oxidized low density 
lipoprotein (LDL)  
•  Macrophage uptake of oxidized LDL and aPL 
causes macrophage activation and endothelial 
damage 
Stimulation of platelet function  •  Anti-ß2-Glycoprotein I antibodies bind to 
platelets, endothelial cells, and monocytes  
•  Leads to the expression of tissue factor and 
platelet aggregation 
Other proteins important in the 
coagulation cascade may be targeted 
by aPL including prothrombin, 
protein C and S, and annexin V 
•  aPL antibodies bind and cause decreased protein 
C activation, decreased antithrombin III activity, 
decreased Annexin V binding, decreased 
fibrinolysis, and increased tissue factor activity  
“Second hit”  •  Other factors may play a role in whether patients 
develop clinical manifestations of APS 
•  These include vascular injury, nonimmunologic 
procoagulant factors, or infection subsequently 
causing endothelial cell activation and 
thrombosis 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
aPL=Antiphospholipid 
antibodies  
ELISA=Enzyme-linked 
immunosorbent assay 
APS=Antiphospholipid 
syndrome   
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VI.  Diagnostic Criteria/Sapporo Criteria
7,12-13 
1.  Original Sapporo criteria 1999 
i.  Clinical criteria 
1.  Vascular thrombosis 
2.  Pregnancy morbidity 
ii.  Laboratory criteria 
1.  aCL on 2 or more occasions at least 6 weeks apart 
2.  LA on 2 or more occasions at least 6 weeks apart 
2.  Sapporo criteria revised in 2006 
i.  Include specific definitions for clinical manifestations and laboratory 
titers 
ii.  Include anti- ß2-glycoprotein I antibody as a laboratory item 
iii.  Laboratory time requirement extended from 6 weeks to 12 weeks 
iv.  Specify time interval between laboratory results and clinical 
manifestations 
v.  Recommend classifying patients in clinical trials into different categories 
1.  >1 laboratory criteria present 
2.  LA present alone 
3.  aCL antibody present alone 
4.  Anti- ß2-glycoprotein I antibody present alone 
vi.  Addresses the issue of  patients who (i) meet the laboratory criteria but 
do meet the clinical criteria and (ii) meet the clinical criteria but do not 
meet the laboratory criteria 
1.  These patients are classified as “probable APS”, “features 
associated with APS”, or “non-criteria features of APS” and 
should clearly be distinguished from patients with definite APS 
in clinical trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCL=Anticardiolipin 
antibodies 
LA= Lupus anticoagulant 
APS=Antiphospholipid 
syndrome   
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Table 3: Revised classification criteria for the antiphospholipid syndrome
7 
APS is present if at least one of the clinical criteria and one of the laboratory criteria are met* 
Clinical Criteria 
1  Vascular thrombosis 
•  One or more clinical episodes of arterial, venous, or small vessel thrombosis¶, in any tissue or 
organ confirmed by objective validated criteria (i.e. imaging studies, Doppler studies) 
2.   Pregnancy morbidity  
•  One or more unexplained deaths of a morphologically normal fetus at or beyond the 10
th 
week of gestation with normal fetal morphology documented by ultrasound or by direct 
examination of the fetus or 
•  One or more premature births of a morphologically normal neonate before the 34
th week of 
gestation because of: (i) eclampsia or severe pre-eclampsia or (ii) recognized features of 
placental insufficiency or 
•  Three or more unexplained consecutive spontaneous abortions before the 10
th week of 
gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal 
chromosomal causes excluded 
Laboratory Criteria 
1.  Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 weeks apart 
detected according to the guidelines of the International Society on Thrombosis and Haemostasis§ 
2.  Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in serum or plasma, present in medium or 
high titer (>40 GPL or MPL, or >99
th percentile), on two or more occasions, at least 12 weeks apart, 
measured by a standardized ELISA 
3.  Anti- ß2-glycoprotein I antibody of IgG and/or IgM isotype in serum or plasma (in titer > 99
th 
percentile) present on two or more occasions, at least 12 weeks apart, measured by standardized 
ELISA 
*Classification of APS should be avoided if less than 12 weeks or more than 5 years separate the positive aPL test and clinical 
manifestations  ¶superficial venous thrombosis is not included § Laboratory detection of LA
14  should include prolongation of a PL-
dependent clotting assay, evidence of inhibition demonstrated by mixing studies, evidence of PL dependence, lack of specific 
inhibition of any one coagulation factor 
 
Figure 1: A Schematic Representation of In Vitro Coagulation
15 
 
 
 
                              Source: Derksen RHWM, de Groot PG. Tests for lupus anticoagulant revisited. Thromb Res. 2004: 114; 521-526. 
VII.   
APS=Antiphospholipid 
syndrome     
LA= Lupus anticoagulant 
aCL=Anticardiolipin 
antibodies 
ELISA=Enzyme-linked 
immunosorbent assay 
aPL=Antiphospholipid 
antibodies  
PT= Prothrombin Time 
APTT= Activated partial 
thromboplastin time 
KCT= Kaolin clotting 
time 
CSCT=Colloidal silica 
clotting time 
HMWK=High molecular 
weight kininogen 
RVVT= Russell’s viper 
venom time 
Abbreviations  Page 7 of 19 
VIII.  Thrombophilia screening
16-21 
i.  Primary Prevention of thrombosis 
1.  Consideration for women who are considering oral contraceptive 
use and/or family history of thrombophilia 
ii.  Secondary Prevention of thrombosis 
1.  Thrombophilic work up is not usually recommended for the first 
thrombotic episode 
2.  APS is the exception 
3.  Rates of recurrence 
a.  aPL positive patients with a history of thrombosis are at 
a high rate of recurrence  
b.  Schulman et al. reported a recurrence rate of 29% in 
patients with aCL vs. 14% in those without over a 4 year 
follow up period (RR=2.1, 95% CI 1.3-3.3, p=0.0013) 
c.  Four year mortality rate was 15% in those with 
antibodies vs. 6% in those without antibodies (RR=1.8, 
95% CI 0.9-3.6, p=0.01) 
d.  Patients with clinical manifestations associated with 
APS should receive thrombophilia screening 
 
 
 
 
 
 
 
 
ACLA= Anticardiolipin Antibody 
Source: Schulman S, Svenungsson E, Granqvist S. Anticardiolipin Antibodies Predict Early Recurrence of Thromboembolism and 
Death Among Patients with Venous Thromboembolism following Anticoagulant Therapy. Am J Med.1998;104:332-38. 
 
 
 
IX.  Antithrombotic Treatment
 – How much warfarin is enough? 
1.  Uncertain in those patients who have recurrent thrombotic events 
2.  Minimal evidence is available to support the use of additional antiplatelet agents 
in addition to warfarin 
3.  Guidelines for treatment  recommend various target INRs
22-27 
 
 
Panel  2. Mortality in patients with a first 
episode of venous thromboembolism, 
anticoagulated for 6 months 
Panel 1. Cumulative probability of recurrent 
venous thromboembolism in patients after a 
first episode, anticoagulated for 6 months 
 
Figure 1: Cumulative Probability of Recurrence and Cumulative Death Rate Among 
Patients with Venous Thromboembolism following Anticoagulant Therapy in Patients with 
Anticardiolipin Antibodies
 21 
APS=Antiphospholipid 
syndrome   
aPL=Antiphospholipid 
antibodies  
aCL=Anticardiolipin 
antibodies 
 
   
 
Abbreviations  Page 8 of 19 
Table 4: Treatment Intensity for First Thrombotic Event 
Guidelines  CHEST 2008
23  British Committee for  Standards 
in Hematology 2005
25 
International Consensus 
Committee Guidelines 2002
27 
Target INR  2.5  2.5  - 
Recommendation  In patients who have a lupus 
inhibitor and who have no 
additional risk factors and no 
lack of response to therapy, a 
target INR of 2.5 (INR range 2-
3) is appropriate 
A target INR of 2.5 is recommended 
for patient with DVT or PE 
associated with antiphospholipid 
syndrome 
**Stroke due to cerebral infarction in 
APS should be treated with long term 
anticoagulant therapy with a target 
INR of  2.5 
 
Intensity should be based on 
individual risk stratification 
(severity, risk of bleeding) 
Grade of 
Recommendation 
1A: Consistent evidence from 
RCTs without important 
limitations or exceptionally 
strong evidence from 
observational studies 
A: Requires at least one randomized 
controlled trial as part of a body of 
literature of overall good quality and 
consistency addressing specific 
recommendation 
**B: Requires the availability of well 
conducted clinical studies but no 
randomized clinical trials on the 
topic of recommendation 
N/A 
 
 
Table 5: Treatment Intensity for Second Thrombotic Event 
Guidelines  CHEST 2008
23 
 
British Committee for  Standards 
in Hematology 2005
25,26 
International Consensus 
Committee Guidelines 2002
27 
Target INR  3.0  3.5  >3.0 
Recommendation  In patients who have recurrent 
thromboembolic events with a 
therapeutic INR, a target INR of 
3.0 (INR range of 2.5-3.5) is 
suggested 
A target INR of 3.5 is recommended 
for patients who suffer recurrence of 
VTE while on warfarin with an INR 
between 2-3 
A high intensity regimen (INR 
>3) is recommended in patients 
with recurrent thrombotic 
events 
Grade of 
Recommendation 
2C:Evidence for at least one 
critical outcome, from 
observational studies,  case 
series, or RCT* but with serious 
flaws; other alternatives may be 
equally reasonable 
 
C: Requires evidence obtained from 
expert committee reports or opinions 
and/or clinical experiences of 
respected authorities 
Indicates an absence of directly 
applicable clinical studies of good 
quality 
N/A 
 
 
Table 6: Treatment Duration for Initial and Recurrent Events 
Guidelines  CHEST 2008
24  British Committee for  Standards 
in Hematology 2005
25,26 
International Consensus 
Committee Guidelines 2002
27 
Recommended 
Duration 
Initial: After 3months of 
anticoagulant therapy, all 
patients with unprovoked VTE 
should be evaluated for the risk-
to-benefit ratio of long-term 
therapy 
Initial: At least 6 months after an 
initial venous thrombotic event   
Recurrent venous thrombosis should 
be treated long term 
Long-term warfarin treatment in 
APS patients with DVT and/ or 
PE is preferred 
 
Grade of 
Recommendation 
1C: Evidence for at least one 
critical outcome from 
observational studies, case 
series,or from RCTs with serious 
flaws or indirect evidence 
A: Requires at least one randomized 
controlled trial as part of a body of 
literature of overall good quality and 
consistency addressing specific 
recommendation 
N/A 
RCT=Randomized Controlled Trials  N/A= Not Available    APS=Antiphospholipid syndrome  INR=International Normalized Ratio 
VTE=Venous thromboembolism   DVT=Deep venous thrombosis  PE= Pulmonary Embolism      Page 9 of 19 
 
 
X.  Clinical Trials 
1.  Randomized trials 
 
Crowther MA, Ginsberg JS, Julian J, et al. A Comparison of Two Intensities of Warfarin for 
the prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody 
Syndrome. N Engl J Med. 2003. 349:1133-8. 
Study Design  Prospective, randomized, double blind trial 
Objective  Evaluate whether high-intensity warfarin therapy (INR of 3.1-4)  is more effective 
than moderate intensity (INR 2-3) in preventing recurrent thrombosis 
Number of 
Patients 
114 patients at 13 clinical centers 
•  High intensity: 56  
•  Moderate intensity: 58  
Inclusion Criteria  Confirmed arterial or venous thrombosis 
Positive test for antiphospholipid antibodies on two occasions at least three months 
apart 
•  Presence of lupus anticoagulant, moderate or high titer of IgG anticardiolipin 
antibody, or both 
Exclusion Criteria  Presence of IgM anticardiolipin antibodies alone 
Clinically significant bleeding (e.g., refractory thrombocytopenia) 
History of intracranial hemorrhage, stroke, or gastrointestinal bleeding within the 
previous 3 months 
History of objectively confirmed recurrent thrombosis while receiving warfarin 
targeted to an INR ≥ 2 
Pregnancy or planned pregnancy 
Methods  Patients were stratified according to the presence or absence of previous arterial 
thromboembolism  
Unscheduled INR measurements performed during an episode of recurrent thrombosis 
were obtained; if not obtained, the previous INR reported was recorded 
Follow up data obtained at 3 month intervals; Patients seen twice yearly 
Enrollment extended for an additional 18 months to increase recruitment 
Endpoints  Efficacy outcome: recurrent thrombosis 
Safety outcome: bleeding 
Statistical 
Analysis 
Two-sided alpha error of 5% and power of 80% for sample size (76 patients total:38 
per group) 
Intention-to- treat analysis 
Time to first recurrent thrombotic event compared using log-rank test 
Hazard ratios for recurrent thrombosis were calculated using Cox proportional-
hazards model 
Baseline 
Characteristics 
Mean age: 43 (high intensity) vs. 41 (low intensity) 
Female (%): 48 vs.71 (p value=0.01) 
Venous thrombosis (%): 75 vs. 78 
Systemic lupus erythematosus (%): 18 vs. 10 
IgG anticardiolipin antibody alone (No.): 22 vs. 22 
Lupus anticoagulant alone (No.): 24 vs. 25 
IgG anticardiolipin antibody and lupus anticoagulant (No.): 10 vs. 11 
Thromboembolism within 6 months before randomization (%): 29 vs. 36 
Aspirin therapy at enrollment and throughout the study (%): 14 vs. 10 
Results  Recurrent Thrombosis 
•  8 patients (7%) had recurrent thrombosis 
o  6/56  (10.7%) patients in the high intensity group (0.032/pt-yr) 
o  2/58 (3.4%) patients in the  moderate intensity group (0.013/pt-yr) 
o  Hazard Ratio 3.1, 95% CI 0.6-15.0, p value=0.15  Page 10 of 19 
 
A Comparison of Two Intensities of Warfarin for the prevention of Recurrent Thrombosis 
in Patients with the Antiphospholipid Antibody Syndrome (continued)
 28 
Results  Bleeding 
•  7 patients (6%) had major bleeding 
o  3/56 (5.4%) in the high intensity group (0.027/pt-yr) 
o  4/58 (6.9%) in the moderate intensity group (0.03/pt-yr) 
o  Hazard Ratio 1.9, 95% CI 0.8-4.2, p value=0.13 
o  Annual risk of major bleeding was 2.2% with moderate intensity 
warfarin and 3.6% with high intensity warfarin 
Average INR values  
•  High intensity = 3.3 
o  Above range 17% of the time 
o  Below range 43% of the time 
o  Within range 40% of the time 
•  Moderate intensity= 2.3 
o  Above range 11% of the time 
o  Below range 19% of the time 
o  Within range 71% of the time 
Mean follow up=2.7 years 
Author’s 
Conclusions 
High intensity warfarin therapy is not more effective than moderate intensity for the 
prevention of recurrent thrombosis 
Absolute risk for recurrent thrombosis was low with moderate intensity 
Unable to comment on management in patients with a high risk of bleeding 
No conclusion drawn in regards to concomitant aspirin therapy  
Critique  Did not examine effectiveness of warfarin in the initial 3 months following a first 
episode of thrombosis 
Excluded patients with a high risk of bleeding  
Excluded patients who had previous thrombosis on warfarin 
Excluded patients with a history of stroke within the previous 3 months 
Most patients had a history of venous thrombosis 
No conclusion drawn in regards to concomitant aspirin therapy 
High intensity group out of range 43% of the time  
Small sample size 
Due to exclusion criteria, difficult to apply results to all APS patients 
 
 
Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity 
warfarin vs. conventional antithrombotic therapy for the prevention of recurrent 
thrombosis in patients with the antiphospholipid syndrome (WAPS)
 . J Thromb Haemost. 
2005;3:848-53.  
Study Design  Prospective, randomized open label design 
Objective  Assess if high intensity oral anticoagulation (INR>3) is more effective than moderate 
intensity (INR 2-3) in preventing thrombosis  
Number of 
Patients 
109 patients with clinically confirmed APS 
•  54 patients assigned to high intensity warfarin (INR 3-4.5, target 3.5) 
•  55 patients assigned to moderate intensity warfarin (INR 2-3, target 2.5) 
•  3 patients assigned to aspirin 100mg/day  
Inclusion Criteria  Lupus anticoagulant and/or moderate to high anticardiolipin antibodies measured 6-8 
weeks apart and confirmed history of major arterial or venous thrombosis 
Exclusion Criteria  Age <18 years 
History of recurrent thrombosis during anticoagulant prophylaxis 
Co-morbidities contraindicating oral anticoagulants or any serious illness with a life 
expectancy <3 years 
Pregnancy  Page 11 of 19 
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic 
therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid 
syndrome (WAPS) (continued)
 29 
Methods  Patients were stratified according to history of recurrent thrombosis 
Patients examined at baseline, 3 and 6 months, and then every 12 months 
Frequency of INR and dose adjustments dependent on provider 
Endpoints  Primary end points  
1.)  Vascular death, non fatal major arterial and venous thromboembolic events 
(e.g.,. myocardial infarction, stroke, pulmonary embolism, deep vein 
thrombosis, transient ischemic attack) plus major hemorrhage 
Secondary end points 
        1.) Total, minor, and major thrombotic events,  
  and fatal and non-fatal cerebrovascular and cardiac events 
Statistical 
Analysis 
Intention-to-treat analysis 
Two-tailed alpha error of 5% and power of 80% for sample size (500 patients per 
study arm in a 3-year follow up) 
Cox proportional hazards model utilized for hazard ratios with 95% confidence 
intervals  
Kruskal-Wallis test utilized for continuous variables 
Peto’s method used for pooling of data with results of Crowther et al.  
2 sided p values 
Baseline 
Characteristics 
Mean age at recruitment: 41  
Systemic lupus erythematosus (SLE: 9.3% in high intensity group vs. 16.4% in 
moderate intensity  
Aspirin therapy: 0 vs. 5.5%  
 Aspirin+anticoagulants: 7.4% vs. 5.5%  
Characteristic n (%)  High-Intensity 
Anticoagulation 
Conventional Treatment 
Prior arterial thrombosis   21 (38.9)  23 (41.8) 
Prior venous thrombosis   37 (68.5)  38 (69.1) 
Antiphospholipid antibodies 
Anticardiolipin antibody alone  9 (16.7)  10 (19.2) 
Lupus anticoagulant alone  14 (26.9)  13 (25.0) 
Anticardiolipin antibody and 
lupus anticoagulant 
29 (55.8)  29 (55.8) 
 
Results  Recurrent thrombosis 
•  9 patients (8%) had recurrent thrombosis 
o  6/54 patients (11.1%) in the high intensity group (0.031/pt-yr) 
o  3/55 patients (5.5%) in the moderate intensity group (0.016/pt-yr) 
o  Hazard Ratio 1.97, 95% CI 0.49-7.89, p=0.3383 
Bleeding 
•  5 patients (6%) experienced major bleeding 
o  2/54 patients (3.7%) in the high intensity group (0.010/pt-yr) 
o  3/55 patients (5.5%) in the moderate intensity group (0.016/pt-yr) 
o  Hazard Ratio 0.66, 95% CI 0.11-3.96, p=0.6518 
•  21 patients (19%) experienced minor bleeding 
o  15/54 patients (27.8%) in the high intensity group  
o  6/55 patients (10.9%) in the moderate intensity group 
o  Hazard Ratio 2.92, 95% CI 1.13-7.52, p=0.0269 
Mean INR during follow up was 3.2 in the high intensity group vs. 2.5 moderate 
intensity 
Median follow up= 3.6 years  Page 12 of 19 
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic 
therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid 
syndrome (WAPS) (continued) 
29 
Results  Odds ratios for high intensity anticoagulation vs. conventional treatment in Crowther 
et al. and WAPS 
 
 
Meta analysis of Crowther et al. and WAPS showed a  significantly higher occurrence 
of minor bleeding  and a borderline higher risk of thrombosis with high intensity 
anticoagulation 
Author’s 
Conclusions 
Supported moderate intensity warfarin (INR 2-3, target 2.5)  
High intensity oral anticoagulation is difficult to manage and associated with an 
increase in minor bleeding 
Critique  Excluded those with recurrent thrombosis while receiving oral anticoagulant therapy 
Most patients had a history of venous thrombosis 
Mean INR in high intensity group was 3.2, did not report time in therapeutic range 
Non-blinded treatment allocation 
Trial terminated early  
 
 
2.  Retrospective studies 
 
Khamashta MA, Cuadrado MJ, Mujic F et al. The Management of Thrombosis in the 
Antiphospholipid-Antibody Syndrome. N Engl J Med. 1995;332:993-7.  
Study Design  Retrospective study 
Objective  To assess the efficacy of warfarin, low-dose aspirin, or both in preventing recurrent 
thrombosis  
Number of 
Patients 
147 patients 
•  APS with  SLE=66 patients 
•  APS with lupus-like syndrome=19 patients 
•  Primary APS=62 patients 
Inclusion Criteria  Positive tests for lupus anticoagulants, anticardiolipin antibodies, or both 
History of thrombosis (venous, arterial, or both) 
Exclusion Criteria 
 
History of thrombosis with follow up of less than 1 year or those loss to follow up 
Antiphospholipid antibody syndrome manifested only by recurrent fetal loss with no 
history of thrombosis 
Thrombocytopenia but no history of vascular occlusion 
Antiphospholipid antibodies and thrombosis undocumented by objective tests 
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The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome (continued)
19 
Methods  Treated according to physician 
Three page questionnaire used to obtain patient history 
Categorized into 4 groups 
•  No treatment 
•  Aspirin 75mg 
•  Warfarin low intensity (INR<3) with or without aspirin 
•  Warfarin (INR ≥3) with or without aspirin 
Endpoint  Recurrent thrombosis 
Bleeding complications 
Statistical 
Analysis 
Poisson heterogenecity test with 95% CI used to measure follow up rates 
Thrombosis free survival rates were calculated with the Kaplan-Meier method 
Log rank test was used to compare individual periods of treatment throughout follow 
up 
Proportional hazards regression analysis with the Wald significance test was used to 
examine combined effect of treatments  
Hazard ratios with 95% confidence intervals and p values used to present results 
Bonferroni’s adjustment for multiple comparisons 
Baseline 
Characteristics 
Median age=32 
84% female, 16% male 
Initial thrombosis: Venous=76%; Arterial=46% 
Positive anticardiolipin antibody test=83% 
Positive lupus anticoagulant test=76% 
Results  Comparison of Antithrombotic Treatments Used 
 
Recurrent Thrombosis 
•  101 patients (69%)  had 186 recurrences of thrombosis 
o  Arterial: 52%, venous:40%, both: 8% 
•  Highest rate of thrombosis occurred during the first 6 months after cessation 
of warfarin therapy: Recurrence rate 1.30/year 
Bleeding  
•  Occurred in 29 patients (all treated with high intensity warfarin): 7 were also 
receiving aspirin 
•  Minor bleeding: 22/29 patients; 0.071/patient year, 95% CI 0.047 -0.102 
•  Major bleeding: 7/29 patients; 0.017/patient year, 95% CI 0.007-0.035 
Treatment  No. of 
patients  
Patient-
Years of 
Follow-Up 
Recurrent 
Events 
Events 
Per year 
of follow 
up 
Relative 
Risk (95% 
CI) 
P value 
None  84  280.6  80 (34/46)  0.29  1.00   
Aspirin  70  240.3  43 (5/38)  0.18  063 (0.43-
0.92) 
0.013 
Warfarin  Any      
Treatment 
104  409.8  42 (16/26)  0.10  0.36 (0.24-
0.53) 
<0.001 
 INR<3  67  141.3  32 (14/18)  0.23  0.78 (0.30-
1.69) 
0.531 
       With Aspirin  14  31.4  7 (0/7)  0.22  0.78 (0.30-
1.69) 
0.531 
INR≥3  64  197.3  3 (2/1)  0.015  0.05 (0.01-
0.16) 
<0.0001 
       With Aspirin  17  39.8  0 (0/0)  0  0.00 (0.00-
0.33) 
<0.001 
During 6 months 
after cessation of 
any warfarin 
treatment 
39  16.2  21 (20/1)  1.30  4.55 (2.67-
7.43) 
<0.001 
All  147  946.9  186 
(75/111) 
0.20  -  <0.001  Page 14 of 19 
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Results  Treatment with high intensity warfarin (INR≥3) with or without low-dose aspirin was 
significantly more effective than treatment with low intensity warfarin with or 
without aspirin or aspirin alone (p value < 0.001) 
Median follow-up=6 years 
Author’s 
Conclusions 
High intensity (INR ≥3) warfarin therapy with or without low-dose aspirin is effective 
prophylaxis against venous and arterial thrombosis 
Cessation of warfarin therapy is associated with a high risk of recurrent thrombosis  
Highest risk of recurrence was during the first 6 months after the discontinuation of 
warfarin 
No evidence that low dose aspirin prevented recurrences of thrombosis 
Appropriate to maintain an INR ≥3  
Critique  Retrospective design 
Non-blinded treatment allocation 
Did not report time within INR range or average INR values 
Considered cardiovascular risk factors  
 
 
 Ruiz-Irastorza G, Khamashta MA, Hunt BJ, et al. Bleeding and Recurrent Thrombosis in 
Definite Antiphospholipid Syndrome. Arch Intern Med. 2002; 162: 1164-1169.  
Design  Retrospective cohort study 
Objective  Clarify risks and benefits of oral anticoagulation to a target INR of 3.5 in patients 
with definite APS and previous thrombosis  
Number of 
patients 
66 patients all receiving oral anticoagulation to target INR of 3.5 
Inclusion Criteria 
 
Definite APS according to Sapporo criteria 
History of thrombosis 
Treatment with oral anticoagulation to a target INR of 3.5 (INR range 3-4) during the 
previous 12 months 
Methods  Anticoagulant monitoring provided by local anticoagulation clinic or general 
practitioner 
Performed audit of anticoagulation therapy for each patient 
Calculated proportion of measurements of INR within range in the previous 12 
months 
Endpoints  Recurrent thrombosis  
Major bleeding 
Statistical 
Analysis 
Results expressed as rates of events per 100 patient-years calculated as: 
(Total No. of Events X 100)/Total Person-Years 
CI calculated assuming Poisson distribution 
2-tailed t test utilized to for univariate comparison between continuous variables 
Stepwise logistic regression utilized for clinical variables (e.g., bleeding or 
thrombosis) 
Baseline 
Characteristics 
91% female, 9% male 
94% white, 3% black, 3% Indian 
48% primary APS, 48% SLE, 3% other 
Median age= 40 
Median time receiving anticoagulants=5 years 
Previous manifestations; 77% arterial thrombosis; 58% stroke;48% VTE; 52% 
obstetric 
Results  Thrombosis 
•  Total of 6 patients (9%) had thrombotic recurrences  
o  9.1/100 patient-years, 95% CI 3.3-19.6 
o  4  episodes=arterial; 3 patients had additional risk factors 
(hypertension, cigarette smoking) 
o   2 episodes=venous   Page 15 of 19 
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Results  Bleeding 
•  4 patients experienced major bleeding   
Bleeding Rates 
Type of Bleeding  Events per 100 patient years (95% CI) 
Major  6 (1.6-15) 
Intracranial  1.5 (0.04-8.4) 
Fatal  0 (0-3.7) 
Percentage of INR determinations within the predefined range 
•  INR 3-4: 37% 
•  INR 2-2.9: 31% 
•  INR 4-4.9: 13% 
•  INR <2: 12% 
•  INR >5: 7% 
Author’s 
Conclusions 
Most patients with definite APS and previous thrombosis should be treated to a target 
INR of 3.5 
A higher target INR does not result in a high incidence of intracranial or fatal 
bleeding 
Consider low intensity for those patients at higher risk of bleeding (e.g., elderly, 
history of bleeding episodes)  
Risk of recurrence increases and patients should be treated with oral anticoagulation 
indefinitely 
Critique  Retrospective design 
Small sample size 
Relied on patient interviews 
 
 
 
XI.  Summary 
1.  Patients with APS have a high risk of recurrent thrombotic events, however 
guidelines for treatment with oral anticoagulation treatment recommend varying 
durations of therapy 
2.  Guidelines for treatment with oral anticoagulant treatment in this patient 
population recommend different target INRs 
3.  Retrospective studies and prospective trials report conflicting data on the optimal 
target INR for preventing recurrent thrombosis in patients with definite 
antiphospholipid syndrome according to the 1999 diagnostic criteria 
 
XII.  Conclusions 
1.  Patients may benefit from long-term warfarin therapy due to the risk of recurrent 
thrombotic events 
i.  Assessment of individual patient risk for recurrent thrombotic events and 
major bleeding should be completed 
2.  The intensity of warfarin treatment in this patient population remains unclear 
3.  The role of aspirin in combination with warfarin in preventing recurrent 
thrombotic events remains unclear 
4.  Optimal treatment for arterial thromboembolic events remains controversial 
5.  Randomized clinical trials are needed to assess the safety and efficacy of high 
intensity oral anticoagulation in patients with definite APS according to the 2006 
revised diagnostic criteria 
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XIII.  Practical considerations
31 
1.  A comprehensive work up that includes chronic disease states, concomitant 
medications, assessment of cardiovascular risk factors, and bleeding risk should 
be completed  
2.  Patients may have a prolonged aPTT which can make monitoring patients on 
heparin challenging 
i.  Monitoring anti-factor Xa levels is an alternative 
ii.  Patients could be switched to low molecular weight heparin (LMWH) 
3.  Lupus anticoagulants may affect the prothrombin time and prolong the INR 
complicating warfarin monitoring   
i.  Monitoring chromogenic factor X assay is an alternative 
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Appendix 1:  Other Trials Evaluating Secondary Prophylaxis in Patients with APS according to 1999 Sapporo criteria
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*Patients who died (n=18) were excluded  §Six events not specified 
 
 
Appendix 2:  Other Trials Evaluating Secondary Prophylaxis in Patients with antiphospholipid antibodies
38 
 
Author, Year 
[Reference] 
No. of 
Patients 
Study Design  Thrombotic events 
at diagnosis, 
arterial/venous  
Treatment  Follow Up  Thrombosis Rates  Bleeding Rates 
(Major) 
 
Ames, 2005 
[32] 
67  Prospective 
cohort 
17/50  Warfarin INR <2 
Warfarin INR 2-3 
Warfarin INR 3.1-4 
Warfarin INR >4 
Median 9 weeks 
Median 122 weeks 
Median 9 weeks 
Median 5 weeks 
0 
0.04/pt-yr 
0.1/pt-yr 
0 
0      
0.0057/pt-yr    
0.10/pt-yr   
0   
Derksen, 1993 
[20] 
19  Retrospective 
cohort 
0/19  None 
Warfarin INR 2.5-4.0 
16-248 months  NA  2 patients  
   
Giron-Gonzalez, 
2004 
[33] 
158  Prospective 
cohort 
70/106*  Warfarin INR 2.5-3.5  624 pt-yrs  0.005/pt-yr  0.006/pt-yr  
Munoz-Rodriguez, 
1999  
[34] 
47  Retrospective 
cohort 
19/28  None 
Low-dose aspirin 
Warfarin INR 2.5-3.5 
Median 49 months  91% 
41% 
19% 
4 patients 
Wittkowsky 2006 
[35] 
36  Retrospective  
cohort 
14/16§  Warfarin INR 2-3 
Warfarin INR >3 
62.5 pt-yrs  0.096/pt-yr  0.032/pt-yr  
Author, Year 
[Reference] 
No. of 
Patients 
Study Design  Thrombotic events 
at diagnosis, 
arterial/venous  
Treatment  Follow Up  Thrombosis Rates  Bleeding Rates 
(Major) 
 
Rosove, 1992 
[17] 
70  Retrospective 
cohort 
31/39  None 
Low-dose aspirin 
Warfarin INR <2 
Warfarin INR 2-2.9 
Warfarin INR ≥ 3 
161.2 pt-yrs 
37.8 pt-yrs 
11.3 pt-yrs 
40.9 pt-yrs 
110.2 pt-yrs 
0.19/pt-yr 
0.32/pt-yr 
0.57/pt-yr 
0.07/pt-yr 
0 
0 
0 
0.031/pt-yr (all warfarin 
groups) 
Krnic-Barrie 1997 
[35] 
61  Retrospective 
cohort 
38/23  None 
Low-dose aspirin 
Warfarin 
Warfarin+low-dose aspirin 
124.9 pt-yrs 
36.6 pt-yrs 
63.0 pt-yrs 
30.6 pt-yrs 
0.192 (a)   0.11(v) 
0.082 (a)   0.027(v) 
0.048(a)    0 (v) 
0 (a)          0 (v) 
4 patients 
Levine 2004 
[37] 
720  RCT subgroup 
analysis 
720/0  Low-dose aspirin 
Warfarin INR 1.4-2.8 
2 yrs  22.2% 
26.2% 
NA 
RCT=Randomized Controlled Trials  N/A= Not Available    APS=Antiphospholipid syndrome  INR=International Normalized Ratio VTE=Venous thromboembolism   
M=Major    m=minor    a=arterial      v=venous        pt-yrs=patients years 